E
Telesis Bio, Inc.
TBIO
$0.319
$0.0134.25%
E
Sell
7/6/2023Downgrade
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D- on 7/6/2023 due to a decline in the total return index and volatility index.
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D- on 7/6/2023 due to a decline in the total return index and volatility index.
D
Sell
6/21/2023Upgraded
Telesis Bio, Inc. (TBIO) was upgraded to D- from E+ on 6/21/2023 due to an increase in the volatility index.
Telesis Bio, Inc. (TBIO) was upgraded to D- from E+ on 6/21/2023 due to an increase in the volatility index.
E
Sell
6/2/2023Downgrade
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D- on 6/2/2023 due to a large decline in the growth index, volatility index and total return index. Operating cash flow declined 98.03% from -$5.64M to -$11.17M, EBIT declined 39.16% from -$7.88M to -$10.97M, and earnings per share declined from -$0.2751 to -$0.3748.
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D- on 6/2/2023 due to a large decline in the growth index, volatility index and total return index. Operating cash flow declined 98.03% from -$5.64M to -$11.17M, EBIT declined 39.16% from -$7.88M to -$10.97M, and earnings per share declined from -$0.2751 to -$0.3748.
D
Sell
5/8/2023Upgraded
Telesis Bio, Inc. (TBIO) was upgraded to D- from E+ on 5/8/2023 due to an increase in the volatility index and total return index.
Telesis Bio, Inc. (TBIO) was upgraded to D- from E+ on 5/8/2023 due to an increase in the volatility index and total return index.
E
Sell
4/21/2023Downgrade
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index.
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index.
D
Sell
4/3/2023Upgraded
Telesis Bio, Inc. (TBIO) was upgraded to D- from E+ on 4/3/2023 due to a large increase in the growth index, total return index and volatility index. Operating cash flow increased 62.66% from -$15.1M to -$5.64M, total revenue increased 41.86% from $6.68M to $9.47M, and earnings per share increased from -$0.4172 to -$0.2751.
Telesis Bio, Inc. (TBIO) was upgraded to D- from E+ on 4/3/2023 due to a large increase in the growth index, total return index and volatility index. Operating cash flow increased 62.66% from -$15.1M to -$5.64M, total revenue increased 41.86% from $6.68M to $9.47M, and earnings per share increased from -$0.4172 to -$0.2751.
E
Sell
3/14/2023Downgrade
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D- on 03/14/2023.
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D- on 03/14/2023.
D
Sell
3/2/2023Downgrade
Telesis Bio, Inc. (TBIO) was downgraded to D- from D on 3/2/2023 due to a decline in the volatility index.
Telesis Bio, Inc. (TBIO) was downgraded to D- from D on 3/2/2023 due to a decline in the volatility index.
D
Sell
2/10/2023Upgraded
Telesis Bio, Inc. (TBIO) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index.
Telesis Bio, Inc. (TBIO) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
Telesis Bio, Inc. (TBIO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
2/3/2023Upgraded
Telesis Bio, Inc. (TBIO) was upgraded to D from D- on 2/3/2023 due to an increase in the volatility index and total return index.
Telesis Bio, Inc. (TBIO) was upgraded to D from D- on 2/3/2023 due to an increase in the volatility index and total return index.
D
Sell
1/19/2023Downgrade
Telesis Bio, Inc. (TBIO) was downgraded to D- from D on 1/19/2023 due to a decline in the volatility index and total return index.
Telesis Bio, Inc. (TBIO) was downgraded to D- from D on 1/19/2023 due to a decline in the volatility index and total return index.
D
Sell
12/30/2022Upgraded
Telesis Bio, Inc. (DNAY) was upgraded to D from D- on 12/30/2022 due to an increase in the growth index and valuation index. EBIT increased 22.34% from -$14.49M to -$11.25M, total revenue increased 18.04% from $5.66M to $6.68M, and earnings per share increased from -$0.5038 to -$0.4172.
Telesis Bio, Inc. (DNAY) was upgraded to D from D- on 12/30/2022 due to an increase in the growth index and valuation index. EBIT increased 22.34% from -$14.49M to -$11.25M, total revenue increased 18.04% from $5.66M to $6.68M, and earnings per share increased from -$0.5038 to -$0.4172.
D
Sell
5/31/2022Upgraded
Telesis Bio, Inc. (TBIO) was upgraded to D- from E+ on 05/31/2022.
Telesis Bio, Inc. (TBIO) was upgraded to D- from E+ on 05/31/2022.
E
Sell
5/13/2022Downgrade
Codex DNA, Inc. (DNAY) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, total return index and valuation index. The quick ratio declined from 8.88 to 5.08, and debt to equity increased from 0.18 to 0.2.
Codex DNA, Inc. (DNAY) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, total return index and valuation index. The quick ratio declined from 8.88 to 5.08, and debt to equity increased from 0.18 to 0.2.
D
Sell
5/5/2022Upgraded
Codex DNA, Inc. (DNAY) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
Codex DNA, Inc. (DNAY) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
E
Sell
4/20/2022Downgrade
Codex DNA, Inc. (DNAY) was downgraded to E+ from D- on 4/20/2022 due to a major decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 14.34 to 8.88, net income declined 27.15% from -$9.82M to -$12.49M, and debt to equity increased from 0.15 to 0.18.
Codex DNA, Inc. (DNAY) was downgraded to E+ from D- on 4/20/2022 due to a major decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 14.34 to 8.88, net income declined 27.15% from -$9.82M to -$12.49M, and debt to equity increased from 0.15 to 0.18.
D
Sell
3/2/2022Upgraded
Codex DNA, Inc. (DNAY) was upgraded to D- from E on 3/2/2022 due to an increase in the volatility index.
Codex DNA, Inc. (DNAY) was upgraded to D- from E on 3/2/2022 due to an increase in the volatility index.
E
Sell
12/1/2021Upgraded
Codex DNA, Inc. (DNAY) was upgraded to E from E- on 12/1/2021 due to an increase in the valuation index.
Codex DNA, Inc. (DNAY) was upgraded to E from E- on 12/1/2021 due to an increase in the valuation index.
E
Sell
9/13/2021None
Telesis Bio, Inc. (TBIO) was downgraded to E- from U on 09/13/2021.
Telesis Bio, Inc. (TBIO) was downgraded to E- from U on 09/13/2021.
NASDAQ
05/08/2024 4:00PM Eastern
Quotes delayed
